Drug intelligence / Profile preview

HXN5003

Development stage: Phase 1
Lead developer: Helixon
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HXN5003 is a monoclonal antibody that targets the interleukin-4 receptor subunit alpha (IL-4Rα), currently under development by Helixon Biotechnology (Suzhou) Co., Ltd. By specifically binding to the IL-4Rα subunit, HXN5003 inhibits the signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), which are critical cytokines in the mediation of Type 2 (Th2) immune responses. This dual inhibition effectively suppresses the inflammatory cascade associated with allergic conditions. The drug is primarily being investigated for the treatment of atopic dermatitis, with early-stage clinical trials focusing on its safety, tolerability, and pharmacokinetic profile following subcutaneous administration.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on HXN5003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXN5003.

Explore the full profile